Cidara therapeutics to participate in the guggenheim securities smid cap biotech conference

San diego, jan. 30, 2025 (globe newswire) -- cidara therapeutics, inc. (nasdaq: cdtx), a biotechnology company using its proprietary cloudbreak® platform to develop drug-fc conjugate (dfc) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that jeffrey stein, ph.d., president and chief executive officer, will participate in the guggenheim securities smid cap biotech conference.
SMID Ratings Summary
SMID Quant Ranking